HIV – CI

The correct answer is There are no contraindications listed in the manufacturer’s US labeling

The correct answer is There are no contraindications listed in the manufacturer’s labeling.

The correct answer is Hypersensitivity to oseltamivir or any component of the formulation

The correct answer is Patients with severe renal impairment (CrCl <30 mL/minute) or end-stage renal disease (ESRD) who are taking concomitant potent CYP3A inhibitors or inducers

The correct answer is Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation; Hypersensitivity to milk protein concentrate with the buccal tablet

The correct answer is Hypersensitivity to valacyclovir, acyclovir, or any component of the formulation

The correct answer is Hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, toxic skin eruptions) to atazanavir or any component of the formulation; concurrent therapy with alfuzosin, amiodarone (when atazanavir is coadministered with ritonavir), cisapride, elbasvir/grazoprevir, glecaprevir/pibrentasvir, ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine), indinavir, irinotecan, lomitapide, lovastatin, lurasidone (when atazanavir is coadministered with ritonavir), midazolam (oral), nevirapine, pimozide, quinidine (when atazanavir is coadministered with ritonavir), rifampin, sildenafil (when used for pulmonary artery hypertension [eg, Revatio]), simvastatin, St. John’s wort, or triazolam.

The correct answer is Clinically significant hypersensitivity (eg, Stevens-Johnson syndrome) to fosamprenavir, amprenavir, or any component of the formulation;coadministration with drugs highly dependent on CYP3A4 for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (eg, alfuzosin, rifampin, ergot derivatives [eg, dihydroergotamine, ergonovine, ergotamine, methylergonovine], cisapride, St. John’s wort, lovastatin, lomitapide, simvastatin, pimozide, delavirdine, sildenafil [when used for treatment of pulmonary arterial hypertension], midazolam, or triazolam);use of flecainide, lurasidone, or propafenone with concomitant ritonavir therapy.

The correct answer is Coadministration with drugs that are highly dependent on CYP3A for clearance and drugs for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index) (eg, alfuzosin, dronedarone, colchicine [in patients with renal and/or hepatic impairment], ranolazine, ergot derivatives [dihydroergotamine, ergonovine, ergotamine, methylergonovine], cisapride, lurasidone, pimozide, midazolam (oral), triazolam, St. John’s wort, elbasvir/grazoprevir, lomitapide, lovastatin, simvastatin, rifampin, sildenafil [for the treatment of pulmonary hypertension], ivabradine, naloxegol). Must be coadministered with ritonavir; refer to individual monograph for ritonavir for additional contraindication information

The correct answer is Hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, toxic skin eruptions) to efavirenz or any component of the formulation; concurrent administration with elbasvir or grazoprevir

The correct answer is As preexposure prophylaxis in patients with unknown or HIV-1 positive status